GoKawiilFirst you choose a partner, then you choose a genome? For this episode of FC Explains, Fast Company Senior Writer Ainsley Harris digs into the rapidly growing world of embryo genetic screening, including IVF startups like Orchid and Nucleus that offer parents the ability to select embryos based on genome sequencing. Proponents say this kind […] First you choose a partner, then you choose a genome? For this episode of FC Explains, Fast Company Senior Writer Ainsley Harris digs into the rapidly growing world of embryo genetic screening, including IVF startups like Orchid and Nucleus that offer parents the ability to select embryos based on genome sequencing.
We can now choose our baby’s genes. Should we?
Why This Matters
The ability to select embryos based on genetic information marks a significant advancement in reproductive technology, raising ethical questions and potential societal impacts. This development could lead to healthier offspring and more personalized reproductive choices, but also sparks debates about genetic diversity and eugenics. For the tech industry, it highlights the rapid growth of biotech innovations intersecting with data science and ethics.
Key Takeaways
- Embryo genetic screening is becoming more accessible through startups like Orchid and Nucleus.
- This technology enables parents to select embryos based on genetic traits, raising ethical concerns.
- The advancement signifies a merging of biotech and data science with profound implications for society.
Get alerts for these topics